MBI Group announced on Friday that it has completed a project to construct and renovate patient care spaces at The Mount Sinai Hospital's Guggenheim Pavilion, located at 1190 Fifth Avenue on Manhattan's Upper East Side.
The company added that it was selected under a competitive bid process .
Under the four-month project, MBI was responsible for the renovation of patient spaces in the haematology, oncology and bone marrow transplant unit. The renovations of patient rooms, nursing stations, restrooms and corridors included interior demolition, millwork, drywall, ceiling work, tiling, terrazzo, flooring, painting, toilet installation, wall protection, plumbing and HVAC, as well as electrical work.
Founded in 1852, The Mount Sinai Hospital is one of the oldest and largest teaching hospitals in the US. The integrated health care system provides exceptional medical care to local and global communities. It is internationally acclaimed for its excellence in research, patient care, and education across a range of specialties.
Established in 1987, MBI Group is a full-service construction firm providing interior fit-outs and core and shell construction for corporate, educational, healthcare, hospitality, institutional, mixed-use and retail facilities.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval